Remove Molecular Biology Remove Protein Expression Remove Protein Production Remove Vaccine
article thumbnail

Advancements in upstream CLD for enhanced biotherapeutics production

Drug Discovery World

For instance, the engineering of CHO cells, widely used protein expression system, for various metabolic pathways has resulted in improved expression levels of large molecule drugs and product quality 1,2. After engineering, stable clones are screened, identified, and characterised. Biotechnol Bioeng 2012;118:2326.

article thumbnail

Driving efficiency across upstream bioprocess workflow

Drug Target Review

As discussed above, recent advances in gene editing tools and transposon-based vectors have facilitated targeted and consistent cell line engineering for the development of protein expressing CHO cell lines. Anis also serves on the scientific and editorial advisory board of Genetic Engineering News at Mary Ann Liebert, Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The future outlook for mRNA therapies

Drug Discovery World

The biggest growth driver for mRNA therapeutics came from the Covid-19 pandemic, when mRNA-based vaccines proved effective in treating SARS-CoV-2, and pharmaceutical companies such as Pfizer/BioNTech and Moderna were successful in bringing these treatments to market. mRNA is a molecule made up of a single strand of ribonucleic acid (RNA).

Therapies 130
article thumbnail

BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen

The Pharma Data

The Phase II clinical trial will evaluate Ultimovacs’ proprietary universal cancer vaccine, UV1, in combination with AstraZeneca’s durvalumab and olaparib in patients with relapsed ovarian cancer. UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. Mogrify – U.K.-based